Vaxil Bio Ltd
- LAST PRICE0.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0050/ 60
- Ask / Lots0.0050/ 305
- Open / Previous Close--- / 0.0100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vaxil Bio Ltd | 1.4M | -12.5x | --- |
Claritas Pharmaceuticals Inc | 974.6K | -0.3x | --- |
MYND Life Sciences Inc | 1.2M | -4.2x | --- |
Restart Life Sciences Corp | 1.2M | -1.9x | --- |
Zenith Capital Corp | 786.8K | -1.3x | --- |
GeneTether Therapeutics Inc | 775.8K | -1.0x | --- |
Company Information
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Contact Information
- Headquarters
- 3400 One First Canadian PlaceTORONTO, ON, Canada M5X 1A4
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Gadi Levin
- Chief Financial Officer
- Alan Rootenberg
- Independent Director
- Ari Kellen
- Independent Director
- Shawn Langer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 137.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -3.60 |
EPS | $0.00 |
Book Value | $0.01 |
P/E Ratio | -12.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
